Robert Pordy

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Gregory G. Schwartz, Philippe Gabríel Steg, Michael Szarek et al. · New England Journal of Medicine · 2018 · 3.3K citations · Full text

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Jennifer G. Robinson, Michel Farnier, Michel Krempf et al. · New England Journal of Medicine · 2015 · 2.3K citations · Full text

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Frederick E. Dewey, Viktoria Gusarova, Richard L. Dunbar et al. · New England Journal of Medicine · 2017 · 836 citations · Full text

Evinacumab for Homozygous Familial Hypercholesterolemia

Frederick J. Raal, Robert S. Rosenson, Laurens F. Reeskamp et al. · New England Journal of Medicine · 2020 · 707 citations · Full text

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Evan A. Stein, Dan Gipe, Jean Bergeron et al. · The Lancet · 2012 · 575 citations

Metabolic Syndrome, Cardiovascular Disease, Stable Statin Dose +7